论文部分内容阅读
目的:通过荟萃分析探讨间充质干细胞移植治疗急性心肌梗死的安全性和有效性。方法:检索Pubmed、Medline、Cochrane图书馆和Cochrane对照试验注册中心、中国生物医学文献服务系统数据库,应用RevMan 5.3软件进行定量分析。结果:8篇随机对照临床试验共410例纳入本荟萃分析,安全性方面移植组和对照组在全因死亡、移植相关事件、再发心肌梗死、致命性心律失常、免疫系统不良事件中的差异无统计学意义;有效性方面,移植组的左心室射血分数在3、6、12个月时比对照组分别增加9.65%(95%CI:0.89%~18.41%;P=0.03)、3.34%(95%CI:1.48%~5.21%;P=0.0004)、2.56%(95%CI:1.04%~4.09%;P=0.001),均有统计学意义,移植组和对照组在左心室收缩末期容积、左心室舒张末期容积方面的差异无统计学意义。结论:间充质干细胞移植治疗急性心肌梗死不增加主要临床不良事件的风险,在较长时间的随访中有提高左心室功能的作用。
Objective: To investigate the safety and efficacy of mesenchymal stem cell transplantation in the treatment of acute myocardial infarction (AMI) by meta-analysis. Methods: Pubmed, Medline, Cochrane Library and Cochrane Central Register of Controlled Trials, China Biomedical Literature Service Database were searched and quantified using RevMan 5.3 software. Results: A total of 410 RCTs in 8 randomized controlled trials were included in this meta-analysis. The differences between safety and safety groups in all-cause mortality, transplant-related events, recurrent MI, fatal arrhythmia, and adverse events in the immune system In terms of effectiveness, the left ventricular ejection fraction increased by 9.65% (95% CI: 0.89% -18.41%; P = 0.03), 3.34 (95% CI: 1.48% -5.21%; P = 0.0004), 2.56% (95% CI: 1.04% ~ 4.09%, P = 0.001). There were significant differences in the left ventricular systole between the transplantation group and the control group End-volume, left ventricular end-diastolic volume differences were not statistically significant. CONCLUSIONS: Mesenchymal stem cell transplantation in the treatment of acute myocardial infarction does not increase the risk of major clinical adverse events and improves left ventricular function over a longer period of follow-up.